Episurf Medical’s (NASDAQ: EPIS B) first 15 patients have now had their Episealer® implants for more than 3 years. Episurf Medical continues to support the collection of clinical data demonstrating the positive impact Episealer patients experience from the company’s unique, personalised solution for the treatment of knee pain. A significant amount of data has been collected on the growing cohort of Episealer patients, with the first patient still performing very well, nearly 5 years since the treatment. Importantly, the data now shows the clinical relevance and benefits patients experience in their quality of life and the associated reduction in pain. These benefits are seen early and the data positively supports that patients already benefit from the technology within 3 months of their procedure, with benefits continuing to improve in the longer term. Episurf Medical currently has 15 patients who have had the implant for more than 3 years and 4 patients have had the implant for more than 4 years.
"It is reassuring that as time passes, so far, we do not see any deterioration of patient well-being or increase in the need for implant revision" says Prof. Leif Ryd, Senior Medical Advisor to Episurf Medical. “The results are starting to speak for themselves” concludes Prof. Ryd.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CET on 20 July 2017.